Steven Gross

Steven Gross contributed to the discovery that IDH-mutant cancers produce the oncometabolite 2-hydroxyglutarate, a finding that has led to FDA-approved IDH inhibitors for leukemia and has established the paradigm of targeting cancer-specific metabolic enzymes. His metabolomics approaches for identifying oncometabolites have been applied to discover additional cancer-specific metabolic vulnerabilities. His work on cancer metabolism drug development has translated metabolomics discoveries into clinical therapeutics.